Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, 10 Center Drive, 13n240b, Bethesda, MD 20892, USA.
Division of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Urol Clin North Am. 2020 Nov;47(4):457-467. doi: 10.1016/j.ucl.2020.07.004.
Biochemically recurrent prostate cancer represents a stage of prostate cancer where conventional (continued on next page) computed tomography and technetium Tc 99m bone scan imaging are unable to detect disease after curative intervention despite rising prostate-specific antigen. There is no clear standard of care and no systemic therapy has been shown to improve survival. Immunotherapy-based treatments potentially are attractive options relative to androgen deprivation therapy due to the generally more favorable side-effect profile. Biochemically recurrent prostate cancer patients have a low tumor burden and likely lymph node-based disease, which may make them more likely to respond to immunotherapy.
生化复发前列腺癌是前列腺癌的一个阶段，尽管前列腺特异性抗原（PSA）升高，但在经过根治性干预后，常规（续页）计算机断层扫描和锝 Tc 99m 骨扫描成像都无法检测到疾病。目前尚无明确的治疗标准，也没有系统性治疗方法被证明可以改善生存。与雄激素剥夺疗法相比，基于免疫疗法的治疗方法具有更有利的副作用谱，因此可能是更有吸引力的选择。生化复发前列腺癌患者的肿瘤负担较低，且可能存在淋巴结疾病，这可能使他们更有可能对免疫疗法产生反应。
